The appropriateness of the use of influenza vaccines: Recommendations from the latest seasons in Italy

Paolo Bonanni, Sara Boccalini, Patrizio Zanobini, Nawal Dakka, Chiara Lorini, Francesca Santomauro, and Angela Bechini

Department of Health Sciences, University of Florence, Florence, Italy

ABSTRACT

Influenza is one of the major infectious causes of excess mortality, hospitalization, and an increase in healthcare expenditure in all countries. An increasingly ageing population, and a longer life expectancy have brought about an increase in the quota of chronically ill patients and fragile subsets of the population, exposing many members to influenza-related complications. These complications latter include not only respiratory distress – resulting from both influenza and frequent cases of secondary pneumonia – but also conditions related to ischemic cardiopathy, cerebrovascular accidents or diseases, and diabetes. The primary objective of influenza vaccination is to reduce the number of flu-related cases of complications and deaths. Influenza immunization can obtain these results to a significant degree, though the results may vary from year to year. The spread of the epidemic, the match between the circulating strains and the vaccine strains, and the age and immunity status of the population can influence the impact of vaccination. The aim of the current work is to describe the types of influenza vaccine available on the Italian market and their most appropriate uses and make recommendations, starting from the epidemiology of influenza in Italy.

Epidemiological surveillance in Italy

In Italy, an integrated surveillance system – Influnet – is in place. It involves a seasonal survey of Influenza like Illness (ILI), which is conducted through a network of general practitioners (GPs) and pediatricians. The aim is to estimate the weekly incidence of influenza cases in winter season, to determine the duration and intensity of the epidemic. According to Influnet, ILI affects between 4% and 12% of the Italian population every year. Moreover, since 2009/10, an enhanced surveillance system has been put in place to deal with severe and complicated clinical cases of influenza. Every region in Italy must report to the Ministry of Health and the National Health Institute (ISS) all influenza cases – complicated or severe – that require hospitalization in the Intensive Care Unit (ICU) and/or Extra Corporeal Membrane Oxygenation (ECMO).

In the 2015/16 season in Italy, the influenza epidemic reached its peak in the eighth week of 2016, with 6.1 cases per 1,000 patients. The epidemic (incidence >2.36 cases/1000 patients) lasted 12 weeks. The cumulative incidence was 82 cases/1000 patients, which was, however, low compared with previous seasonal surveys. Cumulative incidence in the paediatric population (0–4 years) was 227/1000, while it was 165/1000 in the 5–14-year-old age group. Predictably, age and incidence are inversely related, as demonstrated by the minimal incidence registered among the geriatric population (29/1000 for those aged 65 or older).

With regard to severe disease outcomes, 89 cases were registered in a population with a mean age of 57 years, and 32 confirmed influenza deaths in a population with a mean age of 59 years. Seventy-six percent of those severe cases, and 63% of the deaths surveyed showed the presence of at least one pre-existing chronic disease, for which the influenza vaccine is
recommended. Only 9.7% of these patients with pre-existing chronic conditions (severe cases together with subjects who died) were immunized in the 2015/16 season.8

The 2016/2017 season in Italy has been characterized by an early start and a rapid increase in the circulation of the influenza virus since December 2016. The seasonal peak of the circulation was recorded starting the first week of January, followed by a gradual decrease in the second half of January. The number of estimated cases from the beginning of the surveillance was 5,441,000. According to the calculation of the epidemic thresholds by the Moving Epidemic Method (MEM) developed by the ECDC (European Centre for Disease Prevention and Control), the last season for Italy was classified as a mean intensity season. The highest weekly incidence rates were registered in the age groups of 0–4 years and 5–14 years. Between the end of 2016 and the end of January 2017 two weekly incidence peaks were registered in these two age groups. The values reached 24.9/1000 and 18.5/1000 in the paediatric population (0-4 years) and 13.3/1000 and 11.2/1000 in the 5–14 age group. The cumulative incidence rates were not shown.9

Virological surveillance

The presence of the well-known phenomena of antigenic drift and antigenic shift make the accurate surveillance of the influenza viruses an absolute imperative at the international level. This can be achieved through the identification of pathogens in accredited laboratories. Every year, the World Health Organization (WHO) releases the composition of the vaccine for the forthcoming season, based on the information on the viral strains in circulation and on the ILI-related data collected and presented on the Global Influenza Surveillance Network (WHO).10 In winter 2014/15 in Italy, viruses belonging to the subtype H1N1pdm09 were predominantly isolated (52%), especially compared with H3N2 viral strains (41%). The remaining 7% of the type A strains were not subtyped. Type-B influenza viruses belonging to the B/Yamagata/16/88 and B/Victoria/2/87 lineages were simultaneously in circulation. However, the viruses belonging to the B/Yamagata lineage were largely predominant (97%).11

Over the 2015/16 season, 8,971 clinical samples were tested and analyzed in Italian laboratories: 2,456 (27%) resulted positive to the influenza virus. Strains A and B were in circulation simultaneously, but the type-B viruses were predominant (57%) when compared with type A (43%). As for type A, the subtype H3N2 viruses were mainly isolated and identified (56%) as compared with the H1N1pdm09 strains (35%). The remaining 9% of the type-A strains was not subcategorized. The type-B influenza viruses belonging to the lineages B/Yamagata/16/88 and B/Victoria/2/87 were in circulation at the same time, with a large prevalence of the B/Victoria lineage (95%).11

The results of the 2016/17 season showed a prevalence of influenza type-A strains (95%) belonging to the subtype H3N2 (99% of type-A strains). The phylogenetic analyses of type-B viruses, which represented 4.9% of the positive influenza samples, showed a predominant circulation of viruses belonging to the B/Yamagata lineage (B/Phuket/3073/2013-like virus).12 Data on age distribution of influenza viruses are not available.

For the 2017/18 influenza season in the northern hemisphere, the WHO recommends the following trivalent influenza vaccine (TIV) composition: A/Michigan/45/2015 (H1N1)pdm09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus and B/Brisbane/60/2008-like virus. Quadrivalent influenza vaccines (QIV) should contain the above mentioned three viruses and a B/Phuket/3073/2013-like virus.13

Immunization coverage in Italy

Over the last few years, in Italy, like in many other industrialized countries, a certain degree of skepticism toward vaccinations has increased in the population. This has had clear repercussions in terms of a lower extent of coverage, both in the case of mandatory or recommended vaccines for early childhood, and, predominantly, that of influenza vaccines. Indeed, between 2000/01 and 2016/17 in Italy, the lowest immunization coverage (48.6%) in the elderly population was registered in 2014/15 (Fig. 1). In the last two influenza seasons (2015/16 and 2016/17), vaccination coverage among the elderly increased slightly to 52.0%.14

However, a lot still needs to be done to close the gap that has grown over the last 10 years, and reach the targets established by the National Vaccination Plan 2017/19 (75% as the minimum achievable coverage threshold).15

Vaccines on the Italian market

Split vaccines

Split vaccines are influenza virus particles disrupted by diethyl ether or detergent treatment. While split vaccine does contain all viral proteins, the original viral particulate organization and viral ssRNA are mostly lost. This lead to the loss of some of the inherent immunogenicity of the particle.16 However, due to their adequate immunogenicity, tolerability, and relative ease of production, split vaccines are wide in use. Apart from a TIV formulation, a QIV one has existed since 2014 as well.

Since 1983, with the evolution and co-circulation of two distinct lineages of influenza type-B virus,17 the conventional trivalent influenza vaccines have seemed to show a limited ability to induce effective protection when major or minor mismatches between the influenza B vaccine component and the circulating strains occur.

Figure 1. Influenza vaccination coverage among the elderly (subjects over 65 years) in Italy between 2000/01 and 2016/17.
QIV contains one virus from each of the two influenza B lineages (one B/Victoria virus and one B/Yamagata virus), whereas TIV contains one influenza B virus from one lineage. The results of the clinical trials in all the studied populations — children, adolescents, adults and the elderly — have shown that the Flu-QIV induces an immune response not inferior to that of TIV to the viral strains in common. This indicates the absence of immunological interference after the addition of a fourth viral strain. It is also superior from the immunological point of view with respect to the virus B strain, which is absent in TIVs. The safety profile of the Flu-QIV overlaps with that of the TIVs.

Some impact assessments indicate that compared to the TIV, the use of QIV allows the prevention of additional flu-related cases, hospitalization and death. In particular, the analysis of the cost-effectiveness of the QIV and TIV influenza vaccination have shown that Flu-QIV is more cost-effective compared with the TIVs. In particular, given the risk of a “mismatch” of the TIV with the type B viruses in some influenza seasons, the use of the QIV would lead to a significant reduction in the number of influenza cases and resource-saving associated with such cases. This can partially compensate for the higher cost of the vaccine. In the base case of a cost-effectiveness model applied to the Italian population, it is estimated that the use of QIV vaccines as well, though those are not available on the Italian market. These have moderate immunogenicity and are well tolerated by humans, especially children. However, two doses are needed to guarantee the vaccine’s effectiveness during epidemics.

**Subunit vaccines**

Subunit vaccines contain hemagglutinin (HA) and neuraminidase (NA) purified proteins. They lack inner antigens and lipopolysaccharides. These are frequently used in TIV formulations. They are available for QIV vaccines as well, though those are not available on the Italian market. These have moderate immunogenicity and are well tolerated by humans, especially children. However, two doses are needed to guarantee the vaccine’s effectiveness during epidemics.

**Adjuvanted subunit vaccine**

Adjuvanted inactivated vaccine contains HA and NA purified antigens, adjuvanted with MF59. MF59 is an oil-in-water emulsion, which consists of 150 nm-sized biodegradable squalene oil droplets stabilized by non-ionic surfactants. MF59 adjuvanted trivalent vaccine was licensed in EU, and around 47 million doses have been distributed since 1997. Many studies on its safety and efficacy were carried out between 1997 and 2006. These studies found substantial differences between adjuvanted and non-adjuvanted vaccines in terms of adverse reactions. Unlike aluminum salts, MF59 does not create a deposit of adjuvant and antigen in the injection site. This constitutes a release system that promotes an antigen’s captation in the immune system cells. MF59 also activates immune local cells (rapid activation of linfocitary precursors CD4+) with an immune-strengthening effect. Thanks to its characteristics, it can be recommended for all kinds of population — with respect to age, or chronic conditions determining immunodeficiency, or for those who need any stimulation or enhanced immunogenicity.

The immunogenicity of the MF59 adjuvanted vaccine has been studied in various clinical trials and its advantages in some population groups show consistent results. One of the studies was designed to prove the consistency between the effects of various lots and the profile of antibody response. The methodology compared the efficacy of adjuvanted and non-adjuvanted vaccines on the healthy elderly or adults with chronic diseases. The study’s results showed a better response using adjuvanted vaccine instead of a non-adjuvanted (split) one. The response was better not only for seroconversion but also for antibody geometric mean titer (GMT) increase. The same study also showed a better response not only against homologous but also heterovariant virus strains. So, we can speculate that adjuvanted vaccine gives a broader protection and protects against virus antigenic drift. Adjuvanted influenza vaccines are less likely to be ineffective even when the vaccine strains do not perfectly match the circulating virus strains.

Another study aimed at testing the effectiveness of adjuvanted vaccine included 170,000 vaccinated subjects aged over 65 years in Lombardia, a region in northern Italy. This study analyzed two groups of subjects. In the first one, the subjects were given adjuvanted vaccine (n = 88,449), while in the second group, the subjects were given non-adjuvanted vaccine (n = 82,539), following the local vaccine recommendations. The main outcome was to estimate the risk of hospitalization due to pneumonia related to influenza or influenza-like syndromes. During the three considered seasons (2006/07, 2007/08 and 2008/09) the risk of hospitalization, before each influenza season, was higher for the subjects who were given adjuvanted vaccine (+17%), because they generally were more frail than subjects who were given TIV. Nevertheless, in the peak influenza weeks, 25% less hospitalization was recorded for the adjuvanted group compared with the non-adjuvanted one. In fact, Italian health authorities recommended the adjuvanted trivalent influenza (aTIV) vaccine for high-risk patients. Hence, the patients who received the aTIV vaccine were generally older, with more functional limitations and a higher co-morbidity rate. Such patients may, therefore, have a higher baseline hospitalization rate.

In another study, the adjuvanted vaccine was compared with one subunit and one split vaccine among infants and young children. The adjuvanted influenza vaccine had a higher antibody responses to matched and mismatched strains, a faster onset of immunogenicity, a longer duration, and enhanced protection against influenza in young children. There were higher levels of reactogenicity with the adjuvanted vaccine, but most of the events were mild and transient. Rates of unsolicited adverse events, and severe adverse events were similar in all the groups.

**Virosome vaccine**

Virosomes represent a vaccine presentation form that closely mimics the native virus. Virosomes are reconstituted influenza virus envelopes consisting of HA, NA, and viral phospholipids which lack the viral genetic material. Virosomes are
produced from the influenza virus through a detergent solubilization and removal procedure. Functionally reconstituted influenza virosomes preserve the receptor-binding and membrane-fusion activity of the viral HA. These functional characteristics of virosomes form the basis for their enhanced immunogenicity. Since the virosomes lack the viral RNA, the binding and fusion of virosomes to cells do not imply any infection of the cells. The virosome vaccine has high immunogenicity for all age groups, and thanks to the good tolerability, it can be given to children under 12 years (liposomes are the only adjuvants that can be given to children). The dosage of the virosome vaccine is 0.25 ml between six and 35 months, and 0.5 ml for all other age groups.

**Intradermal vaccine**

Beyond the standard intramuscular split vaccines, an intradermal influenza split vaccine has been currently licensed. It has been proven to induce non-inferior immune responses at a 9 µg HA dose compared with the standard 15 µg HA in adults. This dose-sparing effect is likely to be mediated by the high density of antigen presenting cells (APCs) in the skin, which can capture the antigen and transport it to the lymph nodes, or capture the viral antigen after its migration to the lymph nodes. However, the elderly still need a normal dose of 15 µg when they receive an intradermal influenza vaccine. There is no indication for children. It is administered with a micro needle (1.5 mm) 10 times thinner than conventional needles.

**Intranasal vaccine**

Intranasal vaccine consists of the live-attenuated influenza virus. In contrast to inactivated vaccines, the live-attenuated influenza vaccine (LAIV) induces strong mucosal IgA responses and cell-mediated immune responses, which are effective for the prevention of influenza. It is administered intranasally using the supplied prefilled, single-use sprayer containing 0.2 ml of vaccine. About 0.1 ml is sprayed into each nostril. LAIV is approved for use in the 2-18-year-old age group. But the ACIP recommended that the LAIV was not to be used in 2016/17 in light of its low effectiveness against influenza A(H1N1)pdm09 in the United States in 2013/14 and 2015/16. In Italy, the LAIV is authorized by the AIFA (Italian Agency of Medicines), but is not commercialized.

**Influenza vaccination recommendations**

For the influenza season 2016/2017, the CDC continues to recommend a routine annual influenza vaccination for those aged ≥6 months without contraindications. The correct campaign should consider the timing and indications of vaccination for different populations groups.

Optimally, vaccination should be done before the onset of influenza activity in the community. Children aged between six months and eight years, who require two doses for their first influenza vaccination, should receive their first dose as soon as possible after the vaccine becomes available and the second dose at least four weeks later. The majority of adults have a protective antibody response within two weeks of vaccination. Vaccination should continue to be offered as long as the influenza viruses are circulating and the unexpired vaccine is available. Questions related to the ideal time for vaccination have been raised with respect to the early availability of the vaccine compared with the typical onset and the peak of influenza activity. Efforts should be made to ensure that as many people as possible are vaccinated before influenza strikes the community. On the other hand, protective antibody levels decrease over time after the vaccination. Some recent studies have shown that early vaccination of adults, particularly the elderly, might contribute to reduced protection later in the season.

However, it is noteworthy that revaccination is not recommended in the same season. Vaccination programs should be balanced between maximizing the duration of vaccine-induced protection through the season and avoiding missing an opportunity to vaccinate or vaccinating after the onset of influenza.

Table 1 summarizes the recommendations of the CDC and the Italian Ministry of Health to prevent influenza.

Vaccination is particularly important for groups of people who have an increased risk of influenza or related complications.

It is important to improve vaccination among healthcare workers through the knowledge of influenza transmission and vaccination and other multi-component interventions so that they can protect themselves and their patients.

The influenza vaccine is not contraindicated for people who are allergic to eggs but only for those who have shown a severe allergic reaction to influenza vaccines. Studies on the experience of the use of inactivated influenza vaccines, and more recently, LAIV, indicate that severe allergic reactions to the currently available egg-based influenza vaccines are unlikely for those who are allergic to eggs.

The "Vaccine Calendar for life, 2016", is a document that arose from a consolidated partnership between two Italian Scientific Societies – the Italian Society of Hygiene, Preventive Medicine and Public Health (SII) and the Italian Society of Pediatrics (SIP) – and the main federations representing primary care for children, the Italian Federation of Paediatricians (FIMP), and for adults, the Italian Federation of General Medicine (FIMMG). According to the calendar, the vaccine choice is based on the patient’s age and should be treated as follows:

- **Six months through three years:** Subunit/TIV.
- **3–70 years:** Split QIV for risk groups according to national recommendations, except for the patients who need enhanced immunogenicity based on the physician’s advice (intradermal vaccine from 60-year-old subjects or adjuvanted vaccine for people aged over 65 years).
- **>70 years:** Adjuvanted vaccine or high-dose intradermal vaccine for enhanced immune response.

Since 2012, WHO has recommended the development of QIV, which reflects the current epidemiology of influenza more accurately and which would improve the effectiveness of the vaccine, optimizing the control of this public health threat.

Data on the effectiveness of adjuvanted vaccines are still under discussion in scientific literature, especially in terms of reduction of mortality, complications, and the number of hospitalization days. However, against all three homologous strains and the heterologous A strains, the MF59-adjuvanted
Table 1. Vaccination recommendations of the CDC and the Italian Ministry of Health to prevent influenza.

| CDC | Ministry of Health (Italy) |
|-----|-----------------------------|
| All persons aged ≥50 years | All persons aged ≥65 years |
| Adults and children who have chronic pulmonary (including asthma) or cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus) | All persons (over six months of age) with chronic medical conditions: |
| | - chronic pulmonary (including asthma, Chronic Obstructive Pulmonary Disease – COPD, cystic fibrosis, bronchopulmonary dysplasia) |
| | - cardiovascular disorders (including congenital heart diseases) |
| | - diabetes mellitus or metabolic disorders |
| | - chronic liver disease |
| | - chronic renal failure |
| | - neurological/neuromuscular conditions |
| | - cancer |
| | - diseases needing major surgery |
| | - Inflammatory bowel disease and malabsorption |
| Persons who have immunosuppression (including immunosuppression caused by medications or by HIV infection) | Persons who have immunosuppression due to disease or treatment including due to haematological conditions and HIV infection |
| Persons who are extremely obese (BMI ≥40) | Persons with BMI ≥30 |
| All children aged 6 through 59 months | Pregnant women during second and third gestation quarter in the influenza season |
| Women who are or will be pregnant during the influenza season | Children and adolescents (aged 6 months–18 years) who are receiving long-term aspirin therapy and who might be at risk for experiencing Reye syndrome after influenza virus infection |
| Children and adolescents (aged 6 months–18 years) who are receiving long-term aspirin therapy and who might be at risk for experiencing Reye syndrome after influenza virus infection | Residents of nursing homes and other long-term care facilities |
| Residents of nursing homes and other long-term care facilities | Persons who live with or care for persons at higher risk for influenza-related complications |
| Persons who live with or care for persons at higher risk for influenza-related complications | Healthcare workers with patient contact |
| Healthcare workers with patient contact | Public officials offering services which are of major public interest (policemen, firemen, postal workers, etc…) |
| American Indians/Alaska Natives | Personnel and equipment entering into contact with the animals that can be infected by non human influenza viruses (veterinarians, butchers, breeders, etc…) |

Vaccine gives higher rate of seroprotection to subjects aged over 65 years at three or four weeks after vaccination than non-adjuvanted vaccines do. The MF59-adjuvanted vaccine enhances the immunogenicity of influenza vaccination among the elderly and promises to be a strong tool for influenza prevention in populations with known suboptimal response. Immunogenicity can be defined as the ability of a vaccine to induce an immune response, and in the case of the influenza virus, it is measured by the hemagglutination-inhibition (HI) test. For the influenza vaccination, anti-HI antibodies can inhibit the penetration of the virus into the target cells by binding the haemagglutinin. Actually, it is reasonable to use the level of HI antibodies to infer the efficacy of the vaccine when their function is exactly known. Although there is no fixed cut-off for predictive value, some studies conducted on healthy volunteers have shown a clear reverse correlation between the anti-HI antibody level and the probability of being infected. Accordingly, higher anti-HI titers reduce the likelihood of illness, and an inverse relationship exists between anti-HI titers and the attack rate during an epidemic. The protective capacity of the influenza vaccine increases with increasing antibody titers. The data from clinical trials and observation studies on safety and effectiveness attest to the safety of MF-59 and its ability to enhance the effectiveness of influenza vaccines in the elderly and children.

Skills of communication and adequate management of adverse events following vaccinations are of utmost importance for the achievement of immunization coverage. In fact, in Italy, incorrect assessment and the inability to handle information on deaths not related to a vaccine have paradoxically led to an increase in the number of deaths and complications predominantly due to the non-use of influenza vaccines. In the winter 2014/15, which was characterized by high influenza activity, the collapse of the vaccine coverage following the so-called “Fluad case” has heavily influenced the occurrence of a large number of complications, hospital admissions, and deaths in Italy.

Conclusions

The availability of different types of vaccines to prevent influenza illness and the results of their effectiveness and immunogenicity in different age groups or populations at risk should prompt GPs to encourage their patients to undergo influenza vaccination to prevent complications and deaths. Health authorities should give GPs the opportunity to choose the most appropriate vaccines tailored to specific patients.

In conclusion, the use of any influenza vaccine is crucial to avoid complications, hospitalization and death. But the use of the most appropriate vaccine for each patient optimizes the result at a very modest cost. Increasing the value of public health offer through a value-based approach can improve the quality of health services and preserve its sustainability.

Disclosure of potential conflicts of interest

No potential conflicts of interest to declare.

Financial disclosure statement

Authors have not received any funding for this work.
References

1. Vestergaard LS, Nielsen J, Krause TG, Espenhain L, Tersago K, Bustos Sierra N, Denissov G, Inkos N, Vitarian MJ, Fouillet A, et al. Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017. Euro Surveill. 2017;22(14):pii=30506.

2. Rolles MA, Foppa IM, Garg S, Flannery B, Brammer L, Singleton JA, et al. Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination in the United States. 2016 Dec 9 [Date Cited]; https://www.cdc.gov/flu/about/disease/2015-16.htm

3. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the United States: measuring disease burden and costs. Vaccine. 2007;25(27):5086-96. doi:10.1016/j.vaccine.2007.03.046.

4. Siriwardena AN. Increasing evidence that influenza is a trigger for cardiovascular disease. J Infect Dis. 2012;206(11):1636-8. doi:10.1093/infdis/jis598.

5. Italian Network for Surveillance of Influenza - INFLUNET. Report n. 27. 3 May 2017. Available at: http://www.iss.it/it/Italian/index.jsp?menu=35&lang=it&parte=Italian&null

6. Italian Ministry of Health. Circular 19 November 2009. [Date Cited]; https://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf

7. Italian Network for Surveillance of Influenza - INFLUNET. Report n. 27. 3 May 2017. [Date Cited]; https://www.salute.gov.it/imgs/C_17_tavole_19_allegati_itemAllegati_0_fileAllegati_itemFi_le_3_file.pdf.

8. Italian Ministry of Health. National Plan for Vaccination Prevention of Influenza 2017-2019. [Date Cited]; Available at: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf

9. Auewarakul P, Kositanton U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine. 2007;25(4):659-63. doi:10.1016/j.vaccine.2006.08.026.

10. Truccchi C, Alcino C, Orsi A, Pagano C, Barberis I, Grammatico F, Canepa P, Rappazzo E, Bruzzone B, Sticchi L, et al. Fifteen years of epidemiologic, virologic and syndromic influenza surveillance: A focus on type B virus and the effects of vaccine mismatch in Liguria region, Italy. Hum Vaccin Immunother. 2017;13(2):456–463. doi:10.1080/21645515.2017.1264779.

11. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claes Y, Peeters M, Innis BL, Jain V. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis. 2013;13:343. doi:10.1186/1471-2334-13-343.

12. Fluarix-Tetra® Summary of Product Characteristics. [Italian] Available at: https://farmaci.agenziafarmaco.gov.it/alfa/servlet/PdfDown loadServlet?pdfFileName=footer_000231_043132_RCP.pdf&rec=h&sys=C000231&lang=it&null

13. Nicolini E, Zanetti M, La Magna F, De Carolis M, De Gennaro G. Enhanced and persistent immune response against homologous and heterologous strains elicited by an MF59®-adjuvanted influenza vaccine in infants and young children. 2013. V70–29 poster. 7th Vaccine and ISV Congress 2013, 27–29 October 2013 – Sitges Barcelona, Spain. Available at: https://www.researchgate.net/publication/273945702_Enhanced_and Persistent_immuneresponse_against_homologous_and_hetero
